Latest Protease inhibitor Stories
Anadys Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of the leading non-nucleoside polymerase inhibitors currently in development for the treatment of hepatitis C virus.
Tibotec, a pharmaceutical R&D company, has presented positive interim data from Phase IIa hepatitis study which demonstrated the antiviral activity of TMC435, an investigational protease inhibitor being developed by the company for the treatment of chronic hepatitis C virus infection.
SAN FRANCISCO, Nov. 1 /PRNewswire/ -- New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection.
Phenomix, a biopharmaceutical company, has begun administering subjects in a Phase Ia clinical trial of PHX1766, the company's internally discovered, orally available NS3/4A protease inhibitor for the treatment of chronic hepatitis C virus infection.
Phenomix Corporation today announced it has begun administering subjects in a Phase 1a clinical trial of PHX1766, the company's internally discovered, orally available NS3/4A protease inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.
In a new Phase III study that compared Merck & Co., Inc.'s HIV integrase inhibitor ISENTRESS(R) (raltegravir) to efavirenz (one of the leading antiretrovirals prescribed for previously untreated (treatment-naive) HIV-infected patients), ISENTRESS reduced HIV viral load to undetectable levels (less than 50 copies/mL) in 86 percent of patients compared to 82 percent of patients treated with efavirenz in previously untreated HIV patients at Week 48.
BRISBANE, Calif., Sept. 24 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that four abstracts from clinical and in-vitro studies of ITMN-191 (R7227) accepted for presentation at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, Oct. 31 - Nov.
Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) announced today that it has successfully completed dose escalation in the Phase 1 human clinical trial of Vivecon(TM), its HIV viral maturation inhibitor, in healthy volunteers.
ATTENTION BUSINESS/FINANCIAL/HEALTH EDITORS Ambrilia Biopharma Inc. (TSX: AMB) today announced that Dr. Philippe Calais, President and CEO, will present the Company and its projects at the Sachs Associates 8th Annual Biotech in Europe Investor Forum to be held in Zurich, September 23-24.
- The act of burning, scorching, or heating to dryness; the state or being thus heated or dried.
- In medicine, cauterization.